The aim of this study was to detect the expression features of tyrosine kinase receptor B (TrkB) and analyze the possible correlation between TrkB expression and lymph vessel density (LVD) in metastasis of ovarian serous adenocarcinoma.
Methods
An immunohistochemical method was used to evaluate TrkB expression in 139 ovarian tumor sections (103 primary ovarian serous adenocarcinomas and 36 serous adenomas) and investigate the correlation between TrkB expression and LVD, which was estimated by means of VEGFR-3 assessment.
Results
TrkB was significantly upregulated in serous adenocarcinomas and absent in serous adenomas. There was no association between TrkB expression and the histological grade of cancer cells. The expression of TrkB was correlated with surgico-pathological stage and metastasis in serous adenocarcinomas. The level of TrkB was higher in advanced-stage than in early-stage disease. TrkB was overexpressed in metastatic lesions compared with the corresponding primary lesions. Furthermore, a positive correlation between TrkB expression and LVD in serous adenocarcinomas was observed.
Conclusions
TrkB was overexpressed in ovarian serous adenocarcinomas and might be involved in cancer metastasis by associated lymphangiogenesis.
KleinR., SmeyneR.J., WurstW., LongL.K., AuerbachB.A., JoynerA.L., BarbacidM.: Targeted disruption of the TrkB neurotrophin receptor gene results in nervous system lesions and neonatal death.Cell, 75: 113–122, 1993.
8.
DoumaS., Van LaarT., ZevenhovenJ., MeuwissenR., Van GarderenE., PeeperD.S.: Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB.Nature, 430: 1034–1039, 2004.
9.
KhwajaA., Rodriguez-VicianaP., WennströmS., WarneP.H., DownwardJ.: Matrix adhesion and ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/AKT cellular survival pathway.EMBO J, 16: 2783–2793, 1997.
10.
YuX., LiuL., CaiB., HeY., WanX.: Suppression of anoikis by the neurotrophic receptor TrkB in human ovarian cancer.Cancer Sci, 99: 543–552, 2008.
11.
SunA., TawfikO., GayedB., ThrasherJ.B., HoestjeS., LiC., LiB.: Aberrant expression of SWI/SNF catalytic subunits BRG1/BRM is associated with tumor development and increased invasiveness in prostate cancers.Prostate, 67: 203–213, 2007.
12.
WeidnerN.: Intratumor microvessel density as a prognostic factor in cancer.Am J Pathol, 147: 9–19, 1995.
13.
PensonR.T., ShannonK.E., SharplessN.E., SeidenM.V.: Ovarian cancer: an update on genetics and therapy.Compr Ther, 24: 477–487, 1998.
14.
AgarwalR., KayeS.B.: Ovarian cancer: strategies for overcoming resistance to chemotherapy.Nat Rev Cancer, 3: 502–516, 2003.
15.
FidlerI.J.: The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited.Nat Rev Cancer, 3: 453–458, 2003.
16.
GeigerT.R., PeeperD.S.: The neurotrophic receptor TrkB in anoikis resistance and metastasis: a perspective.Cancer Res, 65: 7033–7036, 2005.
17.
HoR., EggertA., HishikiT., MinturnJ.E., IkegakiN., FosterP., CamorattoA.M., EvansA.E., BrodeurG.M.: Resistance to chemotherapy mediated by TrkB in neuroblastomas.Cancer Res, 62: 6462–6466, 2002.
18.
SclabasG.M., FujiokaS., SchmidtC., LiZ., FrederickW.A., YangW., YokoiK., EvansD.B., AbbruzzeseJ.L., HessK.R., ZhangW., FidlerI.J., ChiaoP.J.: Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells.Clin Cancer Res, 11: 440–449, 2005.
19.
RicciA., GrecoS., MariottaS., FeliciL., BronzettiE., CavazzanaA., CardilloG., AmentaF., BisettiA., BarboliniG.: Neurotrophins and neurotrophin receptors in human lung cancer.Am J Respir Cell Mol Biol, 25: 439–446, 2001.
20.
SatohF., MimataH., NomuraT., FujitaY., ShinT., SakamotoS., HamadaY., NomuraY.: Autocrine expression of neurotrophins and their receptors in prostate cancer.Int J Urol, 8: S28–S34, 2001.
21.
PearseR.N., SwendemanS.L., LiY., RafiiD., HempsteadB.L.: A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival.Blood, 105: 4429–4436, 2005.
22.
AuC.W., SiuM.K., LiaoX., WongE.S., NganH.Y., TamK.F., ChanD.C., ChanQ.K., CheungA.N.: Tyrosine kinase B receptor and BDNF expression in ovarian cancers - Effect on cell migration, angiogenesis and clinical outcome.Cancer Lett, 281: 151–161, 2009.
23.
LiottaL.A., KohnE.: Anoikis: cancer and the homeless cell.Nature, 430: 973–974, 2004.
24.
NaoraH., MontellD.J.: Ovarian cancer metastasis: integrating insights from disparate model organisms.Nat Rev Cancer, 5: 355–366, 2005.
25.
GeigerT.R., PeeperD.S.: Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis.Cancer Res, 67: 6221–6229, 2007.
26.
YuY., ZhangS., WangX., YangZ., OuG.: Overexpression of TrkB promotes the progression of colon cancer.APMIS, 118: 188–195, 2010.
27.
HanL., ZhangZ., QinW., SunW.: Neurotrophic receptor TrkB: Is it a predictor of poor prognosis for carcinoma patients?Med Hypotheses, 68: 407–409, 2007.
28.
UndeviaS.D., VogelzangN.J., MauerA.M., JanischL., ManiS., RatainM.J.: Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors.Invest New Drugs, 22: 449–458, 2004.
29.
MarshallJ.L., KindlerH., DeekenJ., BhargavaP., VogelzangN.J., RizviN., LuhtalaT., BoylanS., DordalM., RobertsonP., HawkinsM.J., RatainM.J.: Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.Invest New Drugs, 23: 31–37, 2005.
